Tyrosine kinase inhibitors. 13. Structure - Activity relationships for soluble 7-substituted 4-[(3-bromophenyl)amino]pyrido[4,3-d]pyrimidines designed as inhibitors of the tyrosine kinase activity of the epidermal growth factor receptor

Journal of Medicinal Chemistry

Volumn 40, Issue 24, 1997, Pages 3915-3925

  Thompson, Andrew M ^a   Murray, Donna K ^a   Elliott, William L ^b   Fry, David W ^b   Nelson, James A ^b   Showalter, H D Hollis ^b   Roberts, Bill J ^b   Vincent, Patrick W ^b   Denny, William A ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [(3 BROMOPHENYL)AMINO] 7 [[(4 DIMETHYLAMINO)BUTYL] AMINO]PYRIDO[4,3 D]PYRIMIDINE; 4 [(3 BROMOPHENYL)AMINO] 7 [[3 (4 MORPHOLINO)PROPYL]AMINO]PYRIDO[4,3 D]PYRIMIDINE; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOPHOSPHORYLATION; CANCER INHIBITION; CONTROLLED STUDY; CYTOSTASIS; DRUG SOLUBILITY; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; NUDE MOUSE; SQUAMOUS CELL CARCINOMA; STRUCTURE ACTIVITY RELATION; TUMOR XENOGRAFT;

ANIMALS; CARCINOMA, SQUAMOUS CELL; ENZYME INHIBITORS; HUMANS; MICE; MICE, NUDE; PROTEIN-TYROSINE KINASES; PYRIMIDINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SOLUBILITY; STRUCTURE-ACTIVITY RELATIONSHIP; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 0030773557     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm970366v     Document Type: Article

References (30)

1. Fry, D. W.; Kraker, A. J.; McMichael, A.; Ambroso, L. A.; Nelson, J. M.; Leopold, W. R.; Connors, R. W.; Bridges, A. J. A specific inhibitor of the epidermal growth factor receptor tyrosine kinase. Science 1994, 265, 1093-1095.
2. Rewcastle, G. W.; Denny, W. A.; Bridges, A. J.; Zhou, H.; Cody, D. R.; McMichael, A.; Fry, D. W. Tyrosine kinase inhibitors. 5. Synthesis and structure-activity relationships for 4-[(phenylmethy)amino]-and 4-(phenylamino)quinazolines as potent adenosine 5′-triphosphate binding site inhibitors of the tyrosine kinase domain of the epidermal growth factor receptor. J. Med. Chem. 1995, 38, 3482-3487.
3. Bridges, A. J.; Zhou, H.; Cody, D. R.; Rewcastle, G. W.; McMichael, A.; Showalter, H. D. H.; Fry, D. W.; Kraker, A. J.; Denny, W. A. Tyrosine kinase inhibitors. 8. An unusually steep structure-activity relationship for analogues of 4-(3-bromoanilino)-6,7-dimethoxyquinazoline (PD 153035), a potent inhibitor of the epidermal growth factor receptor. J. Med. Chem. 1996, 39, 267-276.
4. Ward, W. H. J.; Cook, P. N.; Slater, A. M.; Davies, D. H.; Holdgate, G. A.; Green, L. R. Epidermal growth factor receptor tyrosine kinase. Investigation of catalytic mechanism, structure-based searching and discovery of a potent inhibitor. Biochem. Pharmacol. 1994, 48, 659-666.
5. Wakeling, A. E.; Barker, A. J.; Davies, D. H.; Brown, D. S.; Green, L. R.; Cartlidge, S. A.; Woodburn, J. R. Specific inhibition of epidermal growth factor receptor tyrosine kinase by 4-anilinoquinazolines. Breast Cancer Res. Treat. 1996, 38, 67-73.
6. Fry, D. W.; Bridges, A. J. Inhibitors of protein tyrosine kinases. Curr. Opin. Biotechnol. 1995, 6, 662-667.
7. Traxler, P. M. Protein tyrosine kinase inhibitors in cancer treatment. Exp. Opin. Ther. Pat. 1997, 7, 571-588.
8. Jardines, L.; Weiss, M.; Fowble, B.; Greene, M. Neu (c-erbB-2/ HER2) and the epidermal growth factor receptor (EGFR) in breast cancer. Pathobiology 1993, 61, 268-282.
9. Lupu, R.; Lippmann, M. E. The role of erbB-2 signal transduction pathways in human breast cancer. Breast Cancer Res. Treat. 1993, 27, 83-93.
10. Fontana, X.; Ferrari, P.; Namer, M.; Peysson, R.; Salanon, C.; Bussiere, F. C-erb-B2 gene amplification and serum level of C-erb-B2 oncoprotein at primary breast cancer diagnosis. Anticancer Res. 1994, 14, 2099-2104.
11. Hickey, K.; Grehan, D.; Reid, I. M.; Obriain, S.; Walsh, T. N.; Hennessy, T. P. J. Expression of epidermal growth factor receptor and proliferating cell nuclear antigen predicts response of esophageal squamous cell carcinoma to chemoradiotherapy. Cancer 1994, 74, 1693-1698.
12. (a) El-Zayat, A. A. E.; Pingree, T. F.; Mock, P. M.; Clark, G. M.; Otto, R. A.; Von Hoff, D. D. Epidermal growth factor receptor amplification in head and neck cancer. Cancer J. 1991, 4, 375-380.
13. (b) Stanton, P.; Richards, S.; Reeves, J.; Nikolic, M.; Edington, K.; Clark, L.; Robertson, G.; Souter, D.; Mitchell, R.; Hendler, F. J.; Cooke, T.; Parkinson, E. K.; Ozanne, B. W. Epidermal growth factor receptor expression by human squamous cell carcinomas of the head and neck, cell lines and xenografts. Br. J. Cancer 1994, 70, 427-433.
14. Rewcastle, G. W.; Palmer, B. D.; Thompson, A. M.; Bridges, A. J.; Cody, D. R.; Zhou, H.; Fry, D. W.; McMichael, A.; Denny, W. A. Tyrosine kinase inhibitors. 10. Isomeric 4-(3-bromophenyl)amino]pyrido[d]pyrimidines are potent ATP binding site inhibitors of the tyrosine kinase function of the epidermal growth factor receptor. J. Med. Chem. 1996, 39, 1823-1835.
15. Kunkel, M. W.; Hook, K. E.; Howard, C. T.; Przybranowski, S.; Roberts, B. J.; Elliott, W. L.; Leopold, W. R. Inhibition of the epidermal growth factor receptor tyrosine kinase by PD 153035 in human A431 tumors in athymic nude mice. Invest. New Drugs 1996, 13, 295-302.
16. Palmer, B. D.; Trumpp-Kallmeyer, S.; Fry, D. W.; Nelson, J. M.; Showalter, H. D. H.; Denny, W. A. Tyrosine kinase inhibitors. 11. Soluble analogues of pyrrolo-and pyrazoloquinazolines as epidermal growth factor receptor inhibitors: Synthesis, biological evaluation, and modeling of the mode of binding. J. Med. Chem. 1997, 40, 1519-1529.
17. Zajac, W. W., Jr.; Walters, T. R.; Darcy, M. G. Oxidation of amines with 2-sulfonyloxaziridines (Davis' Reagents). J. Org. Chem. 1988, 53, 5856-5860.
18. Utermohlen, W. P., Jr.; Hamilton, C. S. Some derivatives of benzo[h]quinoline. J. Am. Chem. Soc. 1941, 63, 156-159.
19. Perrin, D. D. Dissociation Constants of Organic Bases in Aqueous Solution; Butterworths: London, 1965.
20. Kortum, G.; Vogel, W.; Andrussow, K. Dissociation Constants of Organic Acids in Aqueous Solution; Butterworths: London, 1961.
21. Thompson, A. M.; Rewcastle, G. W.; Tercel, M.; Dobrusin, E. M.; Fry, D. W.; Kraker, A. J.; Denny, W. A. Tyrosine kinase inhibitors. 1. Structure-activity relationships for inhibition of epidermal growth factor receptor tyrosine kinase activity by 2,3dihydro-2-thioxo-1H-indole-3-alkanoic acids and 2,2′-dithiobis(1H-indole-3-alkanoic acids). J Med. Chem. 1993, 36, 2459-2469.
22. Chen, H.; Boiziau, J.; Parker, F.; Maroun, R.; Tocque, B.; Roques, B. P.; Garbay-Jaureguiberry, C. Synthesis and structure-activity studies of a series of [(hydroxybenzyl)amino]salicylates as inhibitors of EGF receptor-associated tyrosine kinase activity. J. Med. Chem. 1993, 36, 4094-4098.
23. Traxler, P. M.; Furet, P.; Mett, H.; Buchdunger, E.; Meyer, T.; Lydon, N. 4-(Phenylamino)pyrrolopyrimidines: potent and selective, ATP site directed inhibitors of the EGF-receptor protein tyrosine kinase. J. Med. Chem. 1996, 39, 2285-2292.
24. Rewcastle, G. W.; Bridges, A. J.; Fry, D. W.; Rubin, J. R.; Denny, W. A. Tyrosine kinase inhibitors. 12. Synthesis and structureactivity relationships for 6-substituted 4-(phenylamino)pyrimido[5,4-d]pyrimidines designed as inhibitors of the epidermal growth factor receptor. J. Med. Chem. 1997, 40, 1820-1826.
25. Jones, J. A.; Howard, C. T.; Roberts, B. J.; Elliott, W. L. In vivo establishment and characterization of a murine fibroblast cell line transfected with the human EGF receptor. Proc. Am. Assoc. Cancer Res. 1994, 35, 499.
26. Gill, G. N.; Weber, W. Purification of functionally active epidermal growth factor receptor protein using a competitive antagonist monoclonal antibody and competitive elution with epidermal growth factor. Methods Enzymol. 1987, 146, 82-88.
27. Schabel, F. M.; Griswold, D. P.; Laster, W. R.; Corbett, T. H.; Lloyd, H. H. Quantitative evaluation of anticancer agent activity in experimental animais. Pharmacol. Ther. 1977, 1, 411-435.
28. Leopold, W. R.; Nelson, J. M.; Plowman, J.; Jackson, R. C. Anthrapyrazoles, a new class of intercalating agents with high-level, broad spectrum activity against murine tumors. Cancer Res. 1985, 45, 5532-5539.
29. Elliott, W. L.; Howard, C. T.; Dykes, D. J.; Leopold, W. R. Sequence and schedule-dependent synergy of trimetrexate in combination with 5-fluorouracil in vitro and in mice. Cancer Res. 1989, 49, 5586-5590.
30. Elliott, W. L.; Roberts, B. J.; Howard, C. T.; Leopold, W. R. Chemotherapy with [SP-4-3-(R)]-[1,1-cyclobutanedicarboxylato(2-)](2-methyl-1,4-butanediamine-N,N') platinum (CI-973, NK121) in combination with standard agents against murine tumors in vivo. Cancer Res. 1994, 54, 4412-4418.